Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12335551 | 0.82 | EPHX1 (0.50) | CACNA1BTDP1GAAMEN1KMT2A | |
| SCHEMBL27711478 | 0.81 | CACNA1B (0.45) | CACNA1BTPSAB1PRSS1TPSD1TPSG1 | |
| SCHEMBL5283279 | 0.80 | EPHX1 (0.52) | CACNA1BTDP1GAACA2MEN1 | |
| SCHEMBL10233014 | 0.80 | ALDH1A1 (0.52) | CACNA1BNAMPTL3MBTL1HDAC1GAA | |
| SCHEMBL1491399 | 0.79 | CACNA1B (0.49) | CACNA1BTPSAB1NAMPTL3MBTL1HDAC3 | |
| SCHEMBL1491397 | 0.79 | CACNA1B (0.49) | CACNA1BTPSAB1NAMPTL3MBTL1HDAC3 | |
| SCHEMBL27264455 | 0.79 | CACNA1B (0.49) | CACNA1BNAMPTL3MBTL1HDAC3HDAC1 | |
| SCHEMBL3180689 | 0.77 | L3MBTL1 (0.61) | NAMPTL3MBTL1HDAC1MAPTTDP1 | |
| SCHEMBL8202738 | 0.77 | CACNA1B (0.48) | CACNA1BTPSAB1NAMPTL3MBTL1HDAC3 | |
| SCHEMBL12072841 | 0.76 | HTR2C (0.53) | NAMPTL3MBTL1GAAFPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| CN-101133060-B | Enzyme inhibitors | CHROMA THERAPEUTICS LTD | 2013-06-05 | — | — | CN | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| CN-101133060-A | Enzyme inhibitors | CHROMA THERAPEUTICS LTD (GB) | 2008-02-27 | — | — | CN | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | CACNA1B 4367/4885TPSAB1 859/4885PRSS1 366/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | CACNA1B 3073/4885TPSAB1 430/4885PRSS1 468/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | CACNA1B 3503/4885TPSAB1 791/4885PRSS1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.